NCT00887601View on ClinicalTrials.gov

BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Dementia
Interventions
DRUG

MK3134

Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.

DRUG

Comparator: Placebo

Placebo capsules only in one of the four treatment periods.

DRUG

Donepezil

Single dose 5 mg donepezil capsules in two of the four treatment periods.

DRUG

MK3134

Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00887601 - BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006) | Biotech Hunter | Biotech Hunter